康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09966 康宁杰瑞制药-B

已收盘 05-06 16:08:10

10.030

-0.120

-1.18%

最高10.170	最低9.750	成交量154.90万
今开10.160	昨收10.150	日振幅4.14%
总市值97.19亿	流通市值97.19亿	总股本9.69亿
成交额1,529万	换手率0.16%	流通股本9.69亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09966","market":"HK","secType":"STK","nameCN":"康宁杰瑞制药-B","latestPrice":10.03,"timestamp":1778054890009,"preClose":10.15,"halted":0,"volume":1549000,"delay":0,"changeRate":-0.011822660098522265,"floatShares":969000000,"shares":969000000,"eps":-0.12,"marketStatus":"已收盘","change":-0.12,"latestTime":"05-06 16:08:10","open":10.16,"high":10.17,"low":9.75,"amount":15289581,"amplitude":0.041379,"askPrice":10.03,"askSize":3000,"bidPrice":9.92,"bidSize":16000,"shortable":3,"etf":0,"ttmEps":-0.133537,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778117400000},"marketStatusCode":5,"adr":0,"listingDate":1576080000000,"exchange":"SEHK","adjPreClose":10.15,"openAndCloseTimeList":[[1778031000000,1778040000000],[1778043600000,1778054400000]],"volumeRatio":1.459091,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09966","defaultTab":"news","newsList":[{"id":"1181956760","title":"康宁杰瑞制药-B 2025年营收5.66亿元 同比下滑并由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=1181956760","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181956760?lang=zh_cn&edition=full","pubTime":"2026-04-28 21:31","pubTimestamp":1777383106,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B是一家专注于抗体偶联药物及双特异性抗体等生物制药创新研发的港股上市公司，致力于靶向肿瘤和自身免疫性疾病治疗。年报显示，截至2025年12月31日止年度，公司实现收入5.66亿元人民币，较2024年的6.40亿元人民币下降约11.5%，但相较2023年2.19亿元人民币则增长逾一倍。受研发投入加大的影响，康宁杰瑞制药-B本年度转为亏损，录得年内亏损1.14亿元人民币，而2024年度则实现约1.66亿元人民币的溢利。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康宁杰瑞制药-B 2025年营收5.66亿元 同比下滑并由盈转亏","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629858434","title":"康宁杰瑞制药-B(09966)授出合共 25万股奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2629858434","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629858434?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:27","pubTimestamp":1776954447,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年4月23日(授出日期)，根据限制性股份奖励计划，本公司决议向两名合资格参与者(奖励承授人)(彼等为本集团雇员)授出合共 25万股奖励股份(奖励股份)，以认购最多合共25万股每股面值0.000002 美元的本公司普通股(股份)，惟须待奖励承授人接纳后方可作实。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629096535","title":"康宁杰瑞制药-B(09966)：KN026新辅助治疗乳腺癌III期临床研究结果获选于2026 ASCO年会 LBA口头报告环节进行展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2629096535","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629096535?lang=zh_cn&edition=full","pubTime":"2026-04-22 12:03","pubTimestamp":1776830598,"startTime":"0","endTime":"0","summary":"KN026-004是一项随机、对照、开放、多中心III期临床研究，旨在评价KN026 联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗及多西他赛±卡铂在HER2阳性早期及局部晚期BC新辅助治疗中的疗效和安全性。KN026联合疗法有望成为HER2阳性早期及局部晚期BC新辅助治疗的全新标准疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","III","BK4134","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177072245","title":"港股异动 | 康宁杰瑞制药-B涨11%，KN026商业化临近，即将贡献新增量","url":"https://stock-news.laohu8.com/highlight/detail?id=1177072245","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177072245?lang=zh_cn&edition=full","pubTime":"2026-04-13 13:13","pubTimestamp":1776057218,"startTime":"0","endTime":"0","summary":"消息面上，康宁杰瑞近日宣布，KN026联合石药自主研发的白蛋白结合型多西他赛，用于新辅助治疗HER2阳性乳腺癌的III期临床研究达到主要终点，标志着中国自主研发的HER2双特异性抗体在头对头III期研究中首次证实疗效超越\"曲妥珠单抗+帕妥珠单抗\"双单抗联合方案。东吴证券此前指出，康宁杰瑞目前进展最快的两款产品KN026源于JSKN003均已与石药集团达成国内合作。","market":"us","thumbnail":"https://community-static.tradeup.com/news/7f33020912239d4b6b185486f8054242","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/7f33020912239d4b6b185486f8054242"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"539122164097d66545bffd1deabe6e8d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627485204","title":"港股异动 | 康宁杰瑞制药-B(09966)早盘涨超12% KN026商业化临近 即将贡献新增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2627485204","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627485204?lang=zh_cn&edition=full","pubTime":"2026-04-13 11:41","pubTimestamp":1776051708,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B早盘涨超12%，截至发稿，涨10.54%，报10.38港元，成交额2791.46万港元。东吴证券此前指出，康宁杰瑞目前进展最快的两款产品KN026源于JSKN003均已与石药集团达成国内合作。其中KN026在25年9月已经提交国内上市申请并获优先审评资格，用于2L HER2阳性胃癌患者，我们预计该适应症有望在2026年上市，如能在6月30日前获批则将有机会参与本年度医保目录谈判，加快KN026放量速度。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"539122164097d66545bffd1deabe6e8d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4588","09966","BK1161","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625824945","title":"康宁杰瑞制药-B(09966)：蒋锐获委任为联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2625824945","media":"智通财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625824945?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:26","pubTimestamp":1775647588,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B(09966)发布公告，程湫滥女士因其有其他工作安排，已提呈辞任联席公司秘书，并不再担任香港联交所证券上市规则第3.05条项下的公司授权代表，自2026年4月8日起生效。蒋锐女士已获委任为联席公司秘书(惟须待联交所授予豁免后方可作实)及授权代表，自2026年4月8日起生效。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_5.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_5.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426130.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103855106","title":"康宁杰瑞制药-B2026年3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1103855106","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103855106?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:35","pubTimestamp":1775637330,"startTime":"0","endTime":"0","summary":"康宁杰瑞生物制药于2026年4月8日公布2026年3月股份变动月报表，报告期截至2026年3月31日。已发行股份总数与库存股份也无变化。截至报告期末，公司已发行股份968,574,697股，库存股份5,719,000股，总计974,293,697股，较上月底保持一致，未发生新增发行、购回或注销。此外，月报中披露的股份期权及限制性股份计划均未导致当月实际新增发行或股份变动。公司声明已遵守香港联交所《上市规则》及相关法律规定，所有股份变动事宜均获董事会批准并履行相关程序。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171497282","title":"异动解读 | KN026临床研究达主要终点，康宁杰瑞制药-B盘中大涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171497282","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171497282?lang=zh_cn&edition=full","pubTime":"2026-04-01 09:41","pubTimestamp":1775007678,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B(09966.HK)今日盘中大涨5.13%，表现强势。消息面上，公司此前公布，与石药集团附属津曼特生物合作开发的KN026联合注射用多西他赛（白蛋白结合型-HB1801）用于人表皮生长因子受体2阳性乳腺癌新辅助治疗的III期临床研究达到预先设定的总体病理完全缓解率“tpCR”的主要终点，结果具有显著的统计学和临床意义。研究结果显示，与现有标准治疗相比，KN026联合HB1801±卡铂显著提高了患者的tpCR。这一积极的研发进展被视为推动公司股价上涨的关键因素，增强了市场对其产品管线未来潜力的信心。该研究的详细数据预计将在近期国际学术会议上公布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623583940","title":"康宁杰瑞制药-B(09966)：KN026新辅助治疗HER2阳性乳腺癌III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2623583940","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623583940?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:03","pubTimestamp":1774955020,"startTime":"0","endTime":"0","summary":"BC是中国女性发病率最高的恶性肿瘤，其中HER2阳性亚型约占20%至30%。该研究旨在比较KN026联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗和多西他赛±卡铂新辅助治疗早期和局部晚期HER2阳性BC的有效性及安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09966","III","BK1161","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623958573","title":"【券商聚焦】东吴证券维持康宁杰瑞制药-B(09966)“买入”评级 指核心产品上市在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2623958573","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623958573?lang=zh_cn&edition=full","pubTime":"2026-03-30 13:08","pubTimestamp":1774847282,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东吴证券发布研报指，康宁杰瑞制药-B 核心产品KN026上市在即，新管线进入临床开发阶段，预计将为公司贡献新增量。维持对公司“买入”评级。核心产品进展方面，KN026已于2025年9月提交国内上市申请并获优先审评资格，预计2026年上市；如能在2026年6月30日前获批，则有机会参与本年度医保目录谈判，加速放量。JSKN003已与石药集团达成合作，其HER2阳性乳腺癌二线及以上适应症预计2026年读出数据并推进申报上市。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NzE2MmQxNjEyNzIzMzUyNjY5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NzE2MmQxNjEyNzIzMzUyNjY5.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977653","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153293212","title":"康宁杰瑞制药-B财年亏损1.139亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1153293212","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153293212?lang=zh_cn&edition=full","pubTime":"2026-03-25 23:41","pubTimestamp":1774453268,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B（9966.HK）公布最新财年业绩，录得净亏损达1.139亿元人民币。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622841070","title":"康宁杰瑞制药-B(09966)发布年度业绩，年内亏损人民币1.14亿元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2622841070","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622841070?lang=zh_cn&edition=full","pubTime":"2026-03-25 23:14","pubTimestamp":1774451655,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布截至2025年12月31日止年度业绩，该公司取得收入人民币5.66亿元，同比减少11.54%;年内亏损人民币1.14亿元，同比盈转亏;每股亏损人民币0.12元。公告称，研发开支由截至2024年12月31日止年度的人民币4.04亿元增加至截至2025年12月31日止年度的人民币5.72亿元，主要由于(i)正在进行的临床试验数目增加;(ii)公司临床研究规模的扩大;及(iii)公司候选药物的临床试验进展。下表列载于所示年度按性质划分的研发开支明细。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MCNHmain","MUCmain","CNHmain","UCmain","BK1161","BK1574","CYB","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155617455","title":"康宁杰瑞制药-B收入下滑，研发投入大幅增长并由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=1155617455","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155617455?lang=zh_cn&edition=full","pubTime":"2026-03-25 22:59","pubTimestamp":1774450752,"startTime":"0","endTime":"0","summary":"于2025年度，康宁杰瑞制药-B录得收入人民币566,235千元，较2024年的人民币640,083千元有所下降。同期销售成本分别为人民币63,546千元及人民币60,316千元，毛利为人民币502,689千元与人民币579,767千元相比有所变动。其他收入则由2024年的人民币62,023千元降至2025年的人民币52,815千元。公司2025年的研发开支为人民币572,161千元，较2024年的人民币404,152千元显著增加；行政开支则从人民币74,607千元上升至人民币83,819千元。融资成本在2025年减少至人民币7,449千元，相比2024年的人民币9,924千元有所下降。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621337490","title":"康宁杰瑞制药-B(09966)：KN026辅助治疗HER2+乳腺癌III期临床研究完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2621337490","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621337490?lang=zh_cn&edition=full","pubTime":"2026-03-24 08:07","pubTimestamp":1774310843,"startTime":"0","endTime":"0","summary":"双靶向联合化疗辅助治疗HER2+ BC 对比仅含曲妥珠单抗的方案，可进一步降低复发风险，其中淋巴结阳性人群的获益最为显著。KN026-007是一项随机、对照、开放、多中心III期临床研究，预计纳入约1,800例术后组织学确认区域淋巴结阳性数量≥4个的可切除HER2+ BC患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4134","09966","III","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620270254","title":"康宁杰瑞制药-B(09966.HK)：JSKN016用于治疗TNBC的III期临床研究完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2620270254","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620270254?lang=zh_cn&edition=full","pubTime":"2026-03-20 08:17","pubTimestamp":1773965823,"startTime":"0","endTime":"0","summary":"格隆汇3月20日丨康宁杰瑞制药-B发布公告，JSKN016用于治疗三阴性乳腺癌的一项III期临床研究已成功完成首例患者给药。TNBC约占所有BC病例的15%至20%。　　JSKN016-301是一项开放、随机、对照、多中心III期临床研究，预计将在中国约60家临床研究中心开展。该研究计划入组经至少二线系统性治疗失败的不可手术切除的局部晚期、复发或转移性TNBC患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260320/32083524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK4134","09966","III","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620123279","title":"康宁杰瑞制药-B(09966)委任王飞为首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2620123279","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620123279?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:52","pubTimestamp":1773831136,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，委任王飞先生为本公司首席财务官，自2026年3月16日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619246368","title":"康宁杰瑞制药-B(09966)：JSKN027的I期临床研究完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2619246368","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619246368?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:39","pubTimestamp":1773664765,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，公司自主研发的程序性死亡配体1╱ 血管内皮生长因子受体2双特异性抗体偶联药物JSKN027治疗晚期恶性实体瘤的I期临床研究已成功完成首例患者给药。JSKN027是公司第五款进入临床研究阶段的ADC，也是全球首款进入临床研究阶段的PD-L1/VEGFR2双抗ADC。基于其细胞毒杀伤、抗血管生成及免疫调节等多重作用机制，JSKN027有望为多种实体瘤治疗提供新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619830157","title":"康宁杰瑞制药-B(09966)：JSKN021的IND申请获CDE正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2619830157","media":"智通财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619830157?lang=zh_cn&edition=full","pubTime":"2026-03-13 08:04","pubTimestamp":1773360243,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B(09966)发布公告，公司自主研发的靶向表皮生长因子受体(EGFR)╱人表皮生长因子受体3(HER3)的双抗双载荷偶联药物(ADC(s))JSKN021新药临床试验(IND)申请，已获国家药监局药品审评中心(CDE)正式受理。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_33.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_33.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","LU1223082519.USD","CDE","LU1223082196.USD","09966","BK1574","BK4017","IND","LU1223083913.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619150947","title":"每日卖空追踪 | 康宁杰瑞制药-B 03月12日卖空量成交3.7万股，卖空比例为2.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619150947","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619150947?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:30","pubTimestamp":1773304244,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B北京时间03月12日，跌4.26%，卖空量成交3.7万股，较上一交易日减少60.64%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163637a46376f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163637a46376f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619965150","title":"王宏伟空降CTO，康宁杰瑞的产业化拐点来了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2619965150","media":"读商时代","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619965150?lang=zh_cn&edition=full","pubTime":"2026-03-12 15:46","pubTimestamp":1773301580,"startTime":"0","endTime":"0","summary":"王宏伟的加入，正好补上了康宁杰瑞最核心的短板——产业化能力。而王宏伟此前在ADC生产工艺优化和制造体系建设方面的经验，正是康宁杰瑞当前最需要的能力。换句话说，康宁杰瑞此时引入王宏伟，并不是为了加强研发，而是为了打通创新药商业化的“最后一公里”。对康宁杰瑞来说，王宏伟的到来更像是一块“产业化拼图”的补齐。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031215535697af1077&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031215535697af1077&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphamab.com","stockEarnings":[{"period":"1week","weight":-0.0714},{"period":"1month","weight":0.1228},{"period":"3month","weight":0.1613},{"period":"6month","weight":-0.0278},{"period":"1year","weight":0.293},{"period":"ytd","weight":0.0357}],"compareEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":0.0311},{"period":"3month","weight":-0.0353},{"period":"6month","weight":-0.0222},{"period":"1year","weight":0.1508},{"period":"ytd","weight":0.0105}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康宁杰瑞生物制药是一家主要从事肿瘤生物制剂研发、制造及商业化的投资控股公司。该公司高度差异化的内部管线由处于不同研发阶段的ADCs、单克隆抗体及双特异性抗体肿瘤药物组成。该公司的候选药物包括KN046（PD-L1/CTLA-4双特异性抗体）, KN026（抗HER2双特异性抗体）, KN035（皮下注射PD-L1）, JSKN003（HER2双表位ADC）等，用于1L sq NSCLC、乳腺癌 2+HER L1、晚期实体瘤、HER2表达实体瘤等适应症。","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.117313},{"month":2,"riseRate":0.571429,"avgChangeRate":0.192959},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.039472},{"month":4,"riseRate":0.857143,"avgChangeRate":0.098183},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.016531},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.029877},{"month":7,"riseRate":0.333333,"avgChangeRate":0.059359},{"month":8,"riseRate":0.333333,"avgChangeRate":0.022561},{"month":9,"riseRate":0.333333,"avgChangeRate":0.158319},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.030396},{"month":11,"riseRate":0.5,"avgChangeRate":0.042537},{"month":12,"riseRate":0.5,"avgChangeRate":-0.017716}],"exchange":"SEHK","name":"康宁杰瑞制药-B","nameEN":"ALPHAMAB-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康宁杰瑞制药-B,09966,康宁杰瑞制药-B股票,康宁杰瑞制药-B股票老虎,康宁杰瑞制药-B股票老虎国际,康宁杰瑞制药-B行情,康宁杰瑞制药-B股票行情,康宁杰瑞制药-B股价,康宁杰瑞制药-B股市,康宁杰瑞制药-B股票价格,康宁杰瑞制药-B股票交易,康宁杰瑞制药-B股票购买,康宁杰瑞制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}